CN108348512B - Pcna抑制剂 - Google Patents

Pcna抑制剂 Download PDF

Info

Publication number
CN108348512B
CN108348512B CN201680066579.9A CN201680066579A CN108348512B CN 108348512 B CN108348512 B CN 108348512B CN 201680066579 A CN201680066579 A CN 201680066579A CN 108348512 B CN108348512 B CN 108348512B
Authority
CN
China
Prior art keywords
unsubstituted
substituted
various embodiments
independently
compound
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
CN201680066579.9A
Other languages
English (en)
Chinese (zh)
Other versions
CN108348512A (zh
Inventor
L·H·马尔卡斯
D·霍内
R·J·希基
顾龙
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
City of Hope
Original Assignee
City of Hope
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=58289682&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CN108348512(B) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by City of Hope filed Critical City of Hope
Priority to CN202110922191.7A priority Critical patent/CN113620833A/zh
Publication of CN108348512A publication Critical patent/CN108348512A/zh
Application granted granted Critical
Publication of CN108348512B publication Critical patent/CN108348512B/zh
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C233/00—Carboxylic acid amides
    • C07C233/64—Carboxylic acid amides having carbon atoms of carboxamide groups bound to carbon atoms of six-membered aromatic rings
    • C07C233/76—Carboxylic acid amides having carbon atoms of carboxamide groups bound to carbon atoms of six-membered aromatic rings having the nitrogen atom of at least one of the carboxamide groups bound to a carbon atom of a hydrocarbon radical substituted by doubly-bound oxygen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C237/00—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by amino groups
    • C07C237/02—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by amino groups having the carbon atoms of the carboxamide groups bound to acyclic carbon atoms of the carbon skeleton
    • C07C237/22—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by amino groups having the carbon atoms of the carboxamide groups bound to acyclic carbon atoms of the carbon skeleton having nitrogen atoms of amino groups bound to the carbon skeleton of the acid part, further acylated
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
    • A61K31/167—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide having the nitrogen of a carboxamide group directly attached to the aromatic ring, e.g. lidocaine, paracetamol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4409—Non condensed pyridines; Hydrogenated derivatives thereof only substituted in position 4, e.g. isoniazid, iproniazid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4418—Non condensed pyridines; Hydrogenated derivatives thereof having a carbocyclic group directly attached to the heterocyclic ring, e.g. cyproheptadine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/472—Non-condensed isoquinolines, e.g. papaverine
    • A61K31/4725—Non-condensed isoquinolines, e.g. papaverine containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/24—Heavy metals; Compounds thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/24—Heavy metals; Compounds thereof
    • A61K33/243—Platinum; Compounds thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/62—Oxygen or sulfur atoms
    • C07D213/63—One oxygen atom
    • C07D213/68—One oxygen atom attached in position 4
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D217/00—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems
    • C07D217/22—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to carbon atoms of the nitrogen-containing ring
    • C07D217/26—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Inorganic Chemistry (AREA)
  • Pain & Pain Management (AREA)
  • Hematology (AREA)
  • Oncology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Pyridine Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Other In-Based Heterocyclic Compounds (AREA)
  • Peptides Or Proteins (AREA)
CN201680066579.9A 2015-09-17 2016-09-16 Pcna抑制剂 Active CN108348512B (zh)

Priority Applications (1)

Application Number Priority Date Filing Date Title
CN202110922191.7A CN113620833A (zh) 2015-09-17 2016-09-16 Pcna抑制剂

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
US201562220014P 2015-09-17 2015-09-17
US62/220,014 2015-09-17
US201662313592P 2016-03-25 2016-03-25
US62/313,592 2016-03-25
US201662340964P 2016-05-24 2016-05-24
US62/340,964 2016-05-24
PCT/US2016/052310 WO2017049206A1 (en) 2015-09-17 2016-09-16 Pcna inhibitors

Related Child Applications (1)

Application Number Title Priority Date Filing Date
CN202110922191.7A Division CN113620833A (zh) 2015-09-17 2016-09-16 Pcna抑制剂

Publications (2)

Publication Number Publication Date
CN108348512A CN108348512A (zh) 2018-07-31
CN108348512B true CN108348512B (zh) 2021-09-03

Family

ID=58289682

Family Applications (2)

Application Number Title Priority Date Filing Date
CN201680066579.9A Active CN108348512B (zh) 2015-09-17 2016-09-16 Pcna抑制剂
CN202110922191.7A Pending CN113620833A (zh) 2015-09-17 2016-09-16 Pcna抑制剂

Family Applications After (1)

Application Number Title Priority Date Filing Date
CN202110922191.7A Pending CN113620833A (zh) 2015-09-17 2016-09-16 Pcna抑制剂

Country Status (11)

Country Link
US (5) US10550070B2 (enExample)
EP (2) EP3349754B9 (enExample)
JP (4) JP6966996B2 (enExample)
KR (2) KR20250026875A (enExample)
CN (2) CN108348512B (enExample)
AU (3) AU2016324158B2 (enExample)
CA (1) CA2999080C (enExample)
ES (1) ES3040726T3 (enExample)
IL (4) IL282400B (enExample)
MX (2) MX2021006326A (enExample)
WO (1) WO2017049206A1 (enExample)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN113620833A (zh) * 2015-09-17 2021-11-09 希望之城 Pcna抑制剂

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10420840B2 (en) * 2015-04-10 2019-09-24 Rll, Llc Anticancer therapeutic agents
US11392971B1 (en) * 2017-12-29 2022-07-19 Groupon, Inc. Methods and systems for generating a supply index indicative of a quality of available supply of merchant promotions
US11551247B1 (en) 2017-12-29 2023-01-10 Groupon, Inc. Methods and systems for determining a travel propensity configured for use in the generation of a supply index indicative of a quality of available supply
BR112023022530A2 (pt) * 2021-04-30 2024-01-16 Hope City Inibidores de pcna e inibidores de egfr para tratamento de câncer
AU2023231620A1 (en) * 2022-03-07 2024-09-12 City Of Hope Pcna inhibitors and uses thereof
WO2025054318A1 (en) * 2023-09-06 2025-03-13 City Of Hope Pcna inhibitors and uses thereof
CN117603081A (zh) * 2023-11-28 2024-02-27 沈阳药科大学 N-(2-((2-(3-甲氧基苯氧基)苯基)氨基)-2-乙酰氧基)-1-萘胺的制备方法
CN120097860A (zh) * 2023-12-05 2025-06-06 杜心赟 增殖细胞核抗原抑制剂、其制备方法、其中间体、其药物组合物和用途
WO2025184571A1 (en) * 2024-03-01 2025-09-04 City Of Hope Pcna inhibitors for the treatment of myc family associated cancers
CN118546074B (zh) * 2024-05-27 2025-06-06 安徽贝克制药股份有限公司 一种氘代增殖细胞核抗原抑制剂及其制备方法和其应用
CN118459363B (zh) * 2024-05-27 2024-12-17 安徽贝克制药股份有限公司 一种氟取代增殖细胞核抗原抑制剂及其制备方法和其应用

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7067506B2 (en) * 2001-03-02 2006-06-27 Icos Corporation Compounds useful for inhibiting Chk1
WO2012173677A2 (en) * 2011-03-23 2012-12-20 Indiana University Research And Technology Corporation Anticancer therapeutic agents

Family Cites Families (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US1295611A (en) * 1916-07-29 1919-02-25 Moritz D Schwartz Metatarsal support.
US1298989A (en) * 1918-11-14 1919-04-01 Reed Foundry & Machine Co Tractor-plow.
US4030910A (en) * 1974-01-22 1977-06-21 The Dow Chemical Company Substituted pyridinyloxy(thio)phenyl -acetamides, -ureas and urea derivatives, herbicidal compositions and methods containing same
US4269829A (en) * 1979-06-18 1981-05-26 Rohm And Haas Company Method and composition for treating helminths containing O,O-dialkyl-N-(substituted phenyl)aminothiocarbonyl phosphoramidates
US4911920A (en) 1986-07-30 1990-03-27 Alcon Laboratories, Inc. Sustained release, comfort formulation for glaucoma therapy
FR2588189B1 (fr) 1985-10-03 1988-12-02 Merck Sharp & Dohme Composition pharmaceutique de type a transition de phase liquide-gel
JP2594486B2 (ja) 1991-01-15 1997-03-26 アルコン ラボラトリーズ インコーポレイテッド 局所的眼薬組成物
US5212162A (en) 1991-03-27 1993-05-18 Alcon Laboratories, Inc. Use of combinations gelling polysaccharides and finely divided drug carrier substrates in topical ophthalmic compositions
US6309853B1 (en) 1994-08-17 2001-10-30 The Rockfeller University Modulators of body weight, corresponding nucleic acids and proteins, and diagnostic and therapeutic uses thereof
FR2723739B1 (fr) * 1994-08-19 1997-02-14 Sanofi Sa Derives de glycinamide, procedes pour leur preparation et medicaments les contenant.
US5783597A (en) 1997-03-04 1998-07-21 Ortho Pharmaceutical Corporation 2,5-disubstituted thiophenes: inhibitors of 5-lipoxygenase and inducible cyclooxygenase (COX-2) enzymes, composition and use
US6258822B1 (en) * 1997-08-06 2001-07-10 Abbott Laboratories Urokinase inhibitors
ID27002A (id) * 1998-03-19 2001-02-22 Vertex Pharma Penghambat-penghambat kaspase
WO1999048859A1 (en) 1998-03-20 1999-09-30 Bristol-Myers Squibb Company Aryloxyanilides and related compounds
JP3966816B2 (ja) * 2000-05-30 2007-08-29 中外製薬株式会社 トロンボポエチン様活性を有する化合物
GB0319126D0 (en) * 2003-08-14 2003-09-17 Smithkline Beecham Corp Chemical compounds
EP1678121A4 (en) 2003-10-24 2007-07-25 Exelixis Inc MODULATORS OF TAO KINASES AND METHODS OF USE
US7459562B2 (en) * 2004-04-23 2008-12-02 Bristol-Myers Squibb Company Monocyclic heterocycles as kinase inhibitors
WO2007079003A2 (en) * 2005-12-29 2007-07-12 Bayer Schering Pharma Aktiengesellschaft Amide inhibitors of leukotriene a4 hydrolase
CN102245174B (zh) * 2008-10-17 2013-11-06 埃克塞利希斯股份有限公司 鞘氨醇-1-磷酸受体拮抗剂与抗微管剂之间的协同作用
CN102256944A (zh) * 2008-10-17 2011-11-23 埃克塞利希斯股份有限公司 鞘氨醇-1-磷酸受体拮抗剂
GB201011411D0 (en) * 2010-07-06 2010-08-18 St Georges Hosp Medical School Therapeutic compounds and their use
MX340490B (es) * 2010-07-13 2016-07-11 F Hoffmann-La Roche Ag * Derivados de pirazolo [1, 5a] pirimidina y de tieno [3, 2b] pirimidina como moduladores de la cinasa asociada al receptor de la interleucina 4 (irak4).
CN103189063B (zh) * 2010-11-01 2016-10-19 宾夕法尼亚州研究基金会 治疗组合物和方法
AU2015223835B2 (en) * 2014-02-28 2019-07-11 Fuso Pharmaceutical Industries, Ltd. Amide derivatives
MX2021006326A (es) 2015-09-17 2022-12-16 Inhibidores de pcna.

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7067506B2 (en) * 2001-03-02 2006-06-27 Icos Corporation Compounds useful for inhibiting Chk1
WO2012173677A2 (en) * 2011-03-23 2012-12-20 Indiana University Research And Technology Corporation Anticancer therapeutic agents

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN113620833A (zh) * 2015-09-17 2021-11-09 希望之城 Pcna抑制剂

Also Published As

Publication number Publication date
CN108348512A (zh) 2018-07-31
HK1258793A1 (en) 2019-11-22
EP3349754B9 (en) 2025-10-22
NZ740817A (en) 2024-03-22
US20210078938A1 (en) 2021-03-18
US10550070B2 (en) 2020-02-04
CA2999080C (en) 2023-11-14
IL294381B1 (en) 2023-03-01
JP2025128193A (ja) 2025-09-02
EP4616910A3 (en) 2025-11-05
US12054447B2 (en) 2024-08-06
IL294381A (en) 2022-08-01
IL282400B (en) 2022-08-01
US10913706B2 (en) 2021-02-09
WO2017049206A1 (en) 2017-03-23
US11345656B2 (en) 2022-05-31
JP2019500315A (ja) 2019-01-10
MX2021006326A (es) 2022-12-16
IL276115A (en) 2020-08-31
KR20180069817A (ko) 2018-06-25
AU2023201501B2 (en) 2024-07-04
IL294381B2 (en) 2023-07-01
US20180339960A1 (en) 2018-11-29
KR20250026875A (ko) 2025-02-25
AU2016324158A1 (en) 2018-04-12
JP6966996B2 (ja) 2021-11-17
US20220340516A1 (en) 2022-10-27
MX2018003301A (es) 2019-02-07
BR112018005331A2 (pt) 2018-10-09
MX382996B (es) 2025-03-13
JP2022028665A (ja) 2022-02-16
JP2024028846A (ja) 2024-03-05
AU2020270487B2 (en) 2022-12-15
CN113620833A (zh) 2021-11-09
CA2999080A1 (en) 2017-03-23
AU2016324158B2 (en) 2020-08-27
JP7399925B2 (ja) 2023-12-18
EP3349754C0 (en) 2025-07-16
US12435030B2 (en) 2025-10-07
US20200216386A1 (en) 2020-07-09
EP3349754A4 (en) 2019-03-20
EP3349754A1 (en) 2018-07-25
US20240343682A1 (en) 2024-10-17
IL258174A (en) 2018-05-31
AU2020270487A1 (en) 2020-12-17
IL276115B (en) 2021-05-31
AU2023201501A1 (en) 2023-04-13
KR102768838B1 (ko) 2025-02-14
ES3040726T3 (en) 2025-11-04
EP4616910A2 (en) 2025-09-17
IL282400A (en) 2021-06-30
IL258174B (en) 2020-08-31
JP7690553B2 (ja) 2025-06-10
EP3349754B1 (en) 2025-07-16

Similar Documents

Publication Publication Date Title
CN108348512B (zh) Pcna抑制剂
KR20240158305A (ko) Pcna 억제제 및 이의 용도
JP2018534243A (ja) アンドロゲン受容体拮抗薬
HK40055283A (en) Pcna inhibitors
HK1258659A1 (en) Pcna inhibitors
HK1258659B (en) Pcna inhibitors
EA048301B1 (ru) Ингибиторы pcna
EA040083B1 (ru) Соединения, ингибирующие pcna, фармацевтические композиции и способы лечения заболеваний, связанных с активностью pcna
BR112018005331B1 (pt) Inibidores de pcna
HK1258793B (en) Pcna inhibitors

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
REG Reference to a national code

Ref country code: HK

Ref legal event code: DE

Ref document number: 1258659

Country of ref document: HK

GR01 Patent grant
GR01 Patent grant